Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBanco Santander Regulatory News (BNC)

Share Price Information for Banco Santander (BNC)

Share Price is delayed by 15 minutes
Get Live Data
1,016.00    0.00 (0.00%)
Bid:
1,022.00
Ask:
1,026.00
Spread: 4.00 (0.391%)
Market Cap: £145.79b
BNC Live PriceLast checked at - London Stock Exchange

Intraday Banco Santander Share Chart

Prospectus Exemption

23 Apr 2026 07:40

RNS Number : 6416B
Banco Santander S.A.
23 April 2026
 

 

 

 

Banco Santander, S.A. ("Banco Santander"), in accordance with the provisions of securities market legislation, hereby announces the following:

 

OTHER RELEVANT INFORMATION

 

In connection with the issuance of up to 334,809,216 new ordinary shares of Banco Santander in the context of its acquisition of Webster Financial Corporation, it is hereby noted that Banco Santander is not required to publish, and will not publish, a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017, on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market and repealing Directive 2003/71/EC, as amended (the "Prospectus Regulation"). Banco Santander has elected to rely on the exemptions set forth in Article 1(4)(da) and Article 1(5)(a) of the Prospectus Regulation.

 

To that end, Banco Santander has today published on its corporate website (www.santander.com) an exemption document (the "Exemption Document"), in accordance with the requirements of Annex IX of the Prospectus Regulation. The Exemption Document has been filed with the National Securities Market Commission (Comisión Nacional del Mercado de Valores, "CNMV") and made available to the public in accordance with Article 21(2) of the Prospectus Regulation. The Exemption Document is available at https://www.santander.com/content/dam/santander-com/es/documentos/aumento-de-capital-para-la-adquisicion-de-webster/exemption-document.pdf

 

The Exemption Document does not constitute a prospectus within the meaning of the Prospectus Regulation and is not subject to review and approval under Article 20 thereof. Accordingly, it has not been reviewed or approved by the CNMV.

 

 

Boadilla del Monte (Madrid), 23 April 2026

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCIJMFTMTJTMIF
Date   Source Headline
6th May 20257:00 amRNSPresentation to analysts about sale of San Polska
6th May 20257:00 amRNSSantander announces sale of 49%of Santander Polska
6th May 20257:00 amRNSAnalysts meeting announcement
30th Apr 202512:41 pmRNSTotal Voting Rights
30th Apr 20257:00 amRNS1Q 2025 Results report & analyst presentation
30th Apr 20257:00 amRNS1Q 2025 Results Press Release
29th Apr 202511:11 amRNSBuyback programme: Transactions 23-28Apr
28th Apr 20251:56 pmRNSSantander statement
23rd Apr 202511:59 amRNS1st Quarter 2025 Results Notice
23rd Apr 202511:11 amRNSBuyback programme: transactions 11-22Apr
11th Apr 202511:13 amRNSBuyback programme: transactions 3-10Apr
4th Apr 20253:09 pmRNS2025 AGM - Resolutions
4th Apr 20257:08 amRNSSantander expects growth & 2025 targets reaffirmed
3rd Apr 202511:13 amRNSBuyback programme: transactions 27Mar-2Apr
31st Mar 20254:07 pmRNSTotal Voting Rights
27th Mar 202511:15 amRNSTransaction in Own Shares
20th Mar 202511:10 amRNSBuyback programme: transactions 13Mar-19Mar
17th Mar 20255:31 pmRNSDirector/PDMR Shareholding
14th Mar 20251:27 pmRNSDirector/PDMR Shareholding
14th Mar 20251:22 pmRNSDirector/PDMR Shareholding
13th Mar 202511:06 amRNSBuyback programme: transactions 6 Mar -12 Mar
6th Mar 202511:14 amRNSBuyback programme: transactions 27 Feb- 5 Mar
5th Mar 20257:00 amRNSDirector/PDMR Shareholding
5th Mar 20257:00 amRNSDirector/PDMR Shareholding
28th Feb 20256:23 pmRNSDirector/PDMR Shareholding
28th Feb 20256:19 pmRNSDirector/PDMR Shareholding
28th Feb 20256:14 pmRNSDirector/PDMR Shareholding
28th Feb 20256:08 pmRNSDirector/PDMR Shareholding
28th Feb 202510:52 amRNSTotal Voting Rights
28th Feb 202510:51 amRNSNotice of AGM
28th Feb 202510:15 amRNS2024 UK Annual Report
27th Feb 202511:12 amRNSBuyback programme: transactions 20Feb-26Feb
26th Feb 20257:00 amRNSDirector/PDMR Shareholding
26th Feb 20257:00 amRNSDirector/PDMR Shareholding
26th Feb 20257:00 amRNSDividend declaration & agreement to call 2025 AGM
20th Feb 202511:12 amRNSBuyback programme: transactions 13Feb-19Feb
19th Feb 20255:46 pmRNSDirector/PDMR Shareholding
14th Feb 20251:10 pmRNSReplaces Invitation to purchase certain instrument
13th Feb 202512:00 pmRNSInvitation to purchase certain instruments
13th Feb 202511:18 amRNSBuyback programme: transactions 6Feb-12Feb
12th Feb 20253:43 pmRNSRating granted by Fitch Ratings
7th Feb 20251:49 pmRNSDirector/PDMR Shareholding
7th Feb 20251:48 pmRNSDirector/PDMR Shareholding
6th Feb 20258:00 amRNSInvitation to purchase certain instruments
5th Feb 20257:00 amRNS2024 Financial report & Earnings presentation
5th Feb 20257:00 amRNS2024 Results - Press release
5th Feb 20257:00 amRNSCommencement of a program to repurchase own shares
31st Jan 20251:14 pmRNSTotal Voting Rights
29th Jan 202512:44 pmRNSForm 8.3 - Smith (DS) PLC
29th Jan 202511:07 amRNSNotice of 2024 Results Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.